Health Canada has approved the t:slim X2 Insulin Pump from Tandem Diabetes Care for sale. This device is designed to be compatible with Dexcom’s G7 and G6 continuous glucose monitoring (CGM) systems. The t:slim X2 features a color touchscreen and can hold up to 300 units of insulin. It incorporates a rechargeable battery with a micro-USB charging port and offers users the flexibility to create up to six customized insulin delivery profiles. Additionally, the pump is designed to integrate easily with multiple CGM sensors, enhancing its versatility and user friendliness.
The standout feature of the t:slim X2 is its Control-IQ technology. This advanced system enhances diabetes management by predicting future glucose levels 30 minutes in advance and automatically adjusting insulin delivery based on these predictions. This proactive approach aims to help users maintain optimal glucose levels more effortlessly.
With the commercial release of the insulin pumps scheduled for the fall, Tandem plans to provide guidance via email to potential customers on choosing between the G7 and G6 CGM platforms. They will also preload the pump with the selected CGM system software before shipping, ensuring a seamless setup process for users.
The Dexcom G7, compatible with the t:slim X2, has several improved features over its predecessor, the Dexcom G6. It is notably 60% smaller, combining the sensor and transmitter into a single compact unit. This system is fully waterproof, making it more durable and convenient for everyday use. The G7 also offers a rapid 30-minute sensor warm-up time and a generous 12-hour grace period for sensor replacements, which contributes to a more user-friendly experience. Enhanced connectivity with various digital health apps is another benefit, granting users broader access to their health data and fostering a more integrated approach to diabetes management.
Both the G7 and G6 systems provide continuous glucose monitoring, delivering glucose readings every five minutes throughout the day and night. They feature predictive alerts for severe glucose drops, such as the “Urgent Low Soon” alert, which activates 20 minutes before glucose levels fall below 3.1 mmol/L. Additionally, there are immediate “Urgent Low” alarms that notify users when glucose levels drop below the critical threshold of 3.1 mmol/L.
This development is part of a broader trend in diabetes management technology, focusing on more seamless integration and real-time data access. For instance, Dexcom recently expanded its diabetes-management offerings by facilitating direct Bluetooth connectivity between its G7 system and the Apple Watch. This feature allows users to monitor their glucose levels in real-time directly from their wrist, without the need for an iPhone. This service is currently available in the U.S., UK, and Ireland, with plans to expand to other markets.
Furthermore, earlier in the year, another innovative product from Dexcom, the Stelo Glucose Biosensor, received FDA approval. This wearable biosensor offers up to two weeks of battery life and provides valuable insights into glucose health, allowing users to track their levels continuously without frequent replacements.
In the competitive field of CGM technologies, Allez Health, a new startup founded by former Dexcom employees, has also made significant strides. The company has developed its CGM platform and successfully secured $60 million in Series A+ financing. This influx of investment underscores the growing interest and potential in advanced CGM solutions aimed at improving quality of life for individuals with diabetes.
As advancements continue in this space, the focus remains on enhancing accuracy, user convenience, and integration with other digital health tools. These developments are paving the way for more proactive, data-driven approaches to diabetes management.
#Tandem #Diabetes #Care #Dexcom #announce #tslim #Insulin #Pump #availability #Canada
